Circulating Tumor DNA–Guided Risk Stratification in Colorectal Cancer: Evolving Evidence and Future Utility

Circulating tumor DNA (ctDNA) has emerged as a promising biomarker in colorectal cancer, offering real-time insight into disease activity, treatment response, and recurrence risk. Dr. Stacey Cohen highlighted the potential of ctDNA-based risk stratification and surveillance in colorectal cancer, discussing its utility, testing approaches, prognostic value, and prospective trials. Longitudinal monitoring of ctDNA shows promise in providing an early warning signal for recurrence. Despite its potential as a prognostic and predictive marker, its routine use awaits additional prospective data and considerations for equitable access.